- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Translational regulation.
Displaying page 1 of 1.
EudraCT Number: 2021-002098-25 | Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:Friedrich-Schiller-Universität Jena | |||||||||||||
Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID) | |||||||||||||
Medical condition: severe COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002874-10 | Sponsor Protocol Number: 2022-3545 | Start Date*: 2022-12-16 |
Sponsor Name:Gustave Roussy | ||
Full Title: Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma | ||
Medical condition: Newly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002642-23 | Sponsor Protocol Number: NVD-CLN01 | Start Date*: 2016-11-28 |
Sponsor Name:Novadip Biosciences | ||
Full Title: A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by inte... | ||
Medical condition: Patients diagnosed with symptomatic degenerative spondylolisthesis grade I or II with an indication for spinal fusion of one vertebral segment (L1-S1). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) PL (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002163-17 | Sponsor Protocol Number: 15-138 | Start Date*: 2018-10-25 |
Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024238-46 | Sponsor Protocol Number: D-III | Start Date*: 2011-12-08 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Ulm | ||||||||||||||||||
Full Title: DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer an... | ||||||||||||||||||
Medical condition: Patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000359-15 | Sponsor Protocol Number: DZB-CS-201 | Start Date*: 2020-02-11 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | |||||||||||||
Full Title: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) | |||||||||||||
Medical condition: urothelial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
